James Shannon

James has served on the Supervisory Board since June 2016 and has been Chair of the Scientific Advisory Board since 2020. James has had an extensive career in drug development and pharma. From 2012 until his retirement in 2015, he was Chief Medical Officer at GlaxoSmithKline. Prior to that, he was Global Head of Pharma Development at Novartis and Senior Vice-President, Clinical Development at Sterling Winthrop Pharmaceuticals. He has previously held board positions at companies including Biotie, Circassia, Crucell, Endocyte, and Cerimon Pharmaceuticals. Mr. Shannon currently is Chairman of the Board at Mannkind Corp, myTomorrows, and Kyowa Kirin NA and holds board positions at Horizon Pharma and Leyden Labs. He received his undergraduate and postgraduate degrees at the Queen’s University of Belfast and is a Member of the Royal College of Physicians.